Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
JMB2002 (Ab2001.08) Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA562771
应用
建议稀释比
已发表文章
产品规格
种属反应
Virus
宿主/亚型
Human
/ IgG1, kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
JMB2002 is a biosimilar monoclonal antibody developed specifically to bind the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 the virus responsible for COVID-19. Produced by Shanghai JiYu Pharmaceutical Technology Co. Ltd JMB2002 is a fully human IgG1 antibody designed using the FeiTai platform. Its structure includes an N297A mutation in the constant region to attenuate Fc function potentially reducing the risk of antibody-dependent enhancement which is a concern in some coronavirus treatments. This mutation alters Fc receptor binding to minimize the likelihood of activating unwanted immune responses. JMB2002 showcases dose-dependent pharmacokinetics with linear correlations observed between dosage and peak plasma concentration making it a promising candidate for therapeutic intervention against COVID-19. The biosimilar is formulated for storage stability allowing long-term preservation in research environments and offering insights into its potential applications in immunotherapy against viral infections.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
